Mayer EL, Ren Y, Wagle N, et al. PACE: a randomized phase ii study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor-positive/human epidermal growth factor receptor-negative metastatic breast cancer J Clin Oncol 2024 Mar 21:JCO2301940 robert.butucaru@medfyle.com Aprile 2024 Leggi abstract
Kumar N, Ehsan S, Banerjee S, et al. The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis J Natl Cancer Inst 2024 Mar 5:djae056 robert.butucaru@medfyle.com Aprile 2024 Leggi abstract
